Proline prodrug of melphalan, prophalan-l, demonstrates high therapeutic index in a murine melanoma model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 67, Issue 3, 2007, Pages 752-758

  Mittal, Sachin ^a   Tsume, Yasuhiro ^a   Landowski, Christopher P ^a   Lee, Kyung Dall ^a   Hilfinger, John M ^b   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TSRL INC   (United States)

Author keywords

Melphalan; Mouse melanoma model; Prodrug; Prolidase; Therapeutic efficacy

Indexed keywords

DEXTRO PROPHALAN; HYDROLASE; MELPHALAN; PRODRUG; PROLINE DERIVATIVE; PROLINE DIPEPTIDASE; PROPHALAN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ACTIVATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; HYDROLYSIS; MELANOMA; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR REGRESSION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BODY WEIGHT; CALORIMETRY; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HYDROLYSIS; INDICATORS AND REAGENTS; MELANOMA, EXPERIMENTAL; MELPHALAN; MICE; MICE, INBRED C57BL; PRODRUGS; PROLINE; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM; SURVIVAL ANALYSIS;

EID: 35348860866     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.03.024     Document Type: Article

References (28)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., and Thun M.J. Cancer statistics, 2004. CA Cancer J. Clin. 54 (2004) 8-29
2. Balch C.M. Cutaneous melanoma: prognosis and treatment results worldwide. Semin. Surg. Oncol. 8 (1992) 400-414
3. Balch C.M., Soong S.J., Murad T.M., Smith J.W., Maddox W.A., and Durant J.R. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1 (1983) 126-134
4. Lotze M.T., Dallal R.M., Kirkwood J.M., and Flickinger J.C. Cutaneous melanoma. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles & Practice of Oncology (2001), Lippincott Williams and Wilkins, Philadelphia, PA 2012-2069 Chapter 42
5. Anderson C.M., Buzaid A.C., and Legha S.S. Systemic treatments for advanced cutaneous melanoma. Oncology (Huntington) 9 (1995) 1149-1158 discussion 1163-1164, 1167-1168
6. Legha S.S. Current therapy for malignant melanoma. Semin. Oncol. 16 (1989) 34-44
7. Dollery C. Melphalan, Therapeutic Drugs (1991), Churchill Livingstone, London
8. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Moscow) 65 (2000) 95-106
9. Nielsen D., Maare C., and Skovsgaard T. Cellular resistance to anthracyclines. Gen. Pharmacol. 27 (1996) 251-255
10. Lowenthal R.M., and Eaton K K. Toxicity of chemotherapy. Hematol. Oncol. Clin. North Am. 10 (1996) 967-990
11. Kerr D.E., Senter P.D., Burnett W.V., Hirschberg D.L., Hellstrom I., and Hellstrom K.E. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 31 (1990) 202-206
12. Vrudhula V.M., Senter P.D., Fischer K.J., and Wallace P.M. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J. Med. Chem. 36 (1993) 919-923
13. Kerr D.E., Li Z., Siemers N.O., Senter P.D., and Vrudhula V.M. Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bioconjug. Chem. 9 (1998) 255-259
14. Heinis C., Alessi P., and Neri D. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Biochemistry 43 (2004) 6293-6303
15. Timar F., Botyanszki J., Suli-Vargha H., Babo I., Olah J., Pogany G., and Jeney A. The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site. Cancer Chemother. Pharmacol. 41 (1998) 292-298
16. Chrzanowski K., Bielawska A., Bielawski K., Wolczynski S., and Palka J. Cytotoxicity and effect on collagen biosynthesis of proline analogue of melphalan as a prolidase-convertible prodrug in cultured human skin fibroblasts. Farmaco 56 (2001) 701-706
17. Chrzanowski K., and Palka J. Proline analogue of melphalan as a prolidase-convertible pro-drug in breast cancer MCF-7 cells. Folia Histochem. Cytobiol. 39 (2001) 209-211
18. Chrzanowski K., Bielawska A., and Palka J. Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells. Farmaco 58 (2003) 1113-1119
19. Mittal S., Song X., Vig B.S., Landowski C.P., Kim I., Hilfinger J.M., and Amidon G.L. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs. Mol. Pharm. 2 (2005) 37-46
20. Mittal S., Song X., Vig B.S., and Amidon G.L. Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma. Pharm. Res. (2007)
21. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein Measurement with the Folin Phenol Reagent. J. Biol. Chem. 193 (1951) 265-275
22. Myara I., Charpentier C., and Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to iminodipeptiduria. Clin. Chim. Acta 125 (1982) 193-205
23. Rooseboom M., Commandeur J.N., and Vermeulen N.P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56 (2004) 53-102
24. Connors T.A. Prodrugs in cancer chemotherapy. Xenobiotica 16 (1986) 975-988
25. Dubowchik G.M., and Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83 (1999) 67-123
26. Pyke C., Ralfkiaer E., Huhtala P., Hurskainen T., Dano K., and Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 52 (1992) 1336-1341
27. Nakajima M., Welch D.R., N Belloni P., and Nicolson G.L. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res. 47 (1987) 4869-4876
28. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., and Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284 (1980) 67-68